Brendan Teehan - Nov 1, 2021 Form 3 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
3
Date filed
11/5/2021, 04:43 PM
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ACAD Common Stock 807 Nov 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ACAD Employee Stock Option (Right to Buy) Nov 1, 2021 Common Stock 52.5K $16.87 Direct F1
holding ACAD Employee Stock Option (Right to Buy) Nov 1, 2021 Common Stock 11K $25.12 Direct F2
holding ACAD Employee Stock Option (Right to Buy) Nov 1, 2021 Common Stock 9.34K $42.81 Direct F3
holding ACAD Employee Stock Option (Right to Buy) Nov 1, 2021 Common Stock 8.15K $49.74 Direct F4
holding ACAD Restricted Stock Units Nov 1, 2021 Common Stock 3.13K Direct F5, F6
holding ACAD Restricted Stock Units Nov 1, 2021 Common Stock 3.86K Direct F6, F7
holding ACAD Restricted Stock Units Nov 1, 2021 Common Stock 4.43K Direct F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the 70,000 shares originally subject to the stock option vested and became exercisable on July 16, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 25% of the shares subject to the Stock Option vested and became exercisable on April 29, 2020, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F3 25% of the shares subject to the Stock Option vested and became exercisable on January 6, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F4 25% of the shares subject to the Stock Option vest and become exercisable on February 23, 2022, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F5 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.
F6 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F7 One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024.
F8 The restricted stock units vest in four equal annual installments beginning February 23, 2022.